Home/Pipeline/Rilzabrutinib

Rilzabrutinib

IgG4-related disease

ClinicalOrphan drug designation

Key Facts

Indication
IgG4-related disease
Phase
Clinical
Status
Orphan drug designation
Company

About Sanofi

Sanofi is one of the world's largest pharmaceutical companies, leveraging artificial intelligence and deep immunology expertise to develop breakthrough treatments and vaccines. With a comprehensive pipeline spanning multiple therapeutic areas and a strong commercial portfolio of established medicines, the company is committed to improving global health outcomes. Their recent focus on AI-powered drug discovery and development positions them at the forefront of pharmaceutical innovation.

View full company profile